PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS REQUIRING BIOLOGIC THERAPY HAVE SIGNIFICANT LEVELS OF BASELINE CO-MORBIDITIES: RESULTS FROM A NATIONAL MULTI-CENTRE REGISTER